HERON THERAPEUTICS, INC. /DE/ (HRTX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 105.94M USD | Gross Profit |
| Revenue | (m) | |
| Cost of products and services | 45.24M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $105.94M | (m) | $45.24M | (m) |
| 2026-03-31 | $107.18M | (m) | $43.53M | (m) |
| 2025-12-31 | $113.56M | (m) | $41.35M | (m) |
| 2025-09-30 | $114.64M | (m) | $40.46M | (m) |
| 2025-06-30 | $111.69M | (m) | $38.00M | (m) |
| 2025-03-31 | $109.86M | (m) | $38.66M | (m) |
| 2024-12-31 | $105.64M | (m) | $38.65M | (m) |
| 2024-09-30 | $99.43M | (m) | $38.30M | (m) |
| 2024-06-30 | $89.31M | (m) | $47.05M | (m) |
| 2024-03-31 | $75.40M | (m) | $56.70M | (m) |
| 2023-12-31 | $61.94M | (m) | $65.11M | (m) |
| 2023-09-30 | (m) | (m) | $67.85M | (m) |
| 2023-06-30 | (m) | (m) | $64.36M | (m) |
| 2023-03-31 | (m) | (m) | $60.37M | (m) |
| 2022-12-31 | $52.80M | (m) | $54.87M | (m) |
| 2022-09-30 | (m) | (m) | $53.19M | (m) |
| 2020-12-31 | $52.45M | (m) | $36.19M | (m) |
| 2020-09-30 | $60.45M | (m) | $42.67M | (m) |
| 2020-06-30 | $73.08M | (m) | $52.70M | (m) |
| 2020-03-31 | $82.49M | (m) | $57.28M | (m) |
| 2019-12-31 | $84.35M | (m) | $61.62M | (m) |
| 2019-09-30 | $82.41M | (m) | $57.32M | (m) |
| 2019-06-30 | $69.19M | (m) | $47.70M | (m) |
| 2019-03-31 | $58.17M | (m) | $39.34M | (m) |
| 2018-12-31 | $49.96M | (m) | $27.51M | (m) |
| 2018-09-30 | $41.41M | (m) | $17.28M | (m) |
| 2018-06-30 | $36.72M | (m) | $10.75M | (m) |
| 2018-03-31 | $32.17M | (m) | $6.54M | (m) |
| 2017-12-31 | $26.18M | (m) | (m) | (m) |
| 2017-09-30 | $18.71M | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |